Mauna Kea Technologies Appoints Agnès Rouffiac as Human Resources Director

PARIS--(Marketwire - Sep 13, 2011) - Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the endomicroscopy market, today announced the appointment of Agnès Rouffiac as Director, Human Resources.

With her 20 years of experience in sales, marketing and human resource (HR) management, Ms. Rouffiac will strengthen Mauna Kea Technologies' international HR strategy.

"We are delighted to welcome Agnès to Mauna Kea Technologies," said Sacha Loiseau, Mauna Kea Technologies' CEO and founder. "Her expertise in recruiting top talent to help companies strategically grow and sustain successful businesses will be vital as we work to introduce Cellvizio to new markets and deepen our footprint in healthcare markets where endomicrosopy is currently utilized."

"I am delighted to be joining Mauna Kea Technologies. Following the recent successful IPO, the company is entering an incredibly exciting phase. I believe my expertise in recruitment, business growth and organizational planning will help support the company's business strategy to increase utilization of endomicroscopy in Europe and the rest of the world to ultimately benefit patients and the company's shareholders," Ms. Rouffiac said.

Ms. Rouffiac comes to Mauna Kea from Reckitt Benckiser, the world leader in cleaning and hygiene products, where she worked in roles of increasing responsibility for the last two decades. Most recently, she led HR for Reckitt Beckinser's only industrial facility in France, which employs an estimated 400 people. For the first decade of her career at Reckitt Benckiser, she held key roles in marketing, as a product manager and category leader. In 2002, she was promoted to Trade Marketing Director. Two years later, she began her career as an HR Manager within the same group. Agnès is a graduate of HEC Paris business school and also obtained a Master's in Economics in Brazil (Pontifícia Universidade Católica). She is fluent in French, English and Portuguese.

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company and leader in the endomicroscopy market. The company researches, develops and markets innovative tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI and pulmonary tracts.

For more information about Mauna Kea Technologies visit www.maunakeatech.com

Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Mauna Kea Technologies ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorité des marches financiers ("AMF") granted its visa number 11-236 on June 20, 2011, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.